{"result": {"id": "c569883b-5849-4fb9-9c06-576e0f73d6de", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>舍曲林<|>organization<|>舍曲林 is a selective serotonin reuptake inhibitor (SSRI) used to improve cognitive function with balanced efficacy and tolerability)\n##\n(\"entity\"<|>文拉法辛<|>organization<|>文拉法辛 is a serotonin and norepinephrine reuptake inhibitor (SNRI) effective for anxiety symptoms at high doses)\n##\n(\"entity\"<|>度洛西汀<|>organization<|>度洛西汀 is an SNRI effective for depression with physical pain, similar to 文拉法辛)\n##\n(\"entity\"<|>米氮平<|>organization<|>米氮平 is a noradrenergic and specific serotonergic antidepressant (NaSSA) that improves appetite and sleep with minimal sexual side effects)\n##\n(\"entity\"<|>阿戈美拉汀<|>organization<|>阿戈美拉汀 is a melatonin receptor agonist with good tolerability and sleep-improving effects)\n##\n(\"entity\"<|>曲唑酮<|>organization<|>曲唑酮 is a 5-HT modulator effective for anxiety and sleep, with minimal impact on sexual function)\n##\n(\"entity\"<|>安非他酮<|>organization<|>安非他酮 is a norepinephrine and dopamine reuptake inhibitor (NDRI) used for sexual dysfunction without weight gain)\n##\n(\"entity\"<|>湖南药事服务网<|>organization<|>湖南药事服务网 is a website providing pharmaceutical information)\n##\n(\"entity\"<|>中华全科医师杂志<|>organization<|>中华全科医师杂志 is a medical journal published in December 2021)\n##\n(\"relationship\"<|>舍曲林<|>文拉法辛<|>Both are antidepressants but belong to different classes (SSRI vs. SNRI)<|>3)\n##\n(\"relationship\"<|>文拉法辛<|>度洛西汀<|>Both are SNRIs with similar effects and side effects<|>7)\n##\n(\"relationship\"<|>米氮平<|>阿戈美拉汀<|>Both improve sleep but through different mechanisms (NaSSA vs. melatonin receptor agonist)<|>4)\n##\n(\"relationship\"<|>曲唑酮<|>安非他酮<|>Both are used for depression but have different side effect profiles<|>3)\n##\n(\"relationship\"<|>湖南药事服务网<|>中华全科医师杂志<|>Both are sources of medical and pharmaceutical information<|>2)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558435, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 561, "prompt_tokens": 2520, "total_tokens": 3081, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 728}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 啡因 、苯二氮草类药  物 、卡马西平 、氯氮平 、美沙酮 、 TCAs 浓度升高\n舍曲林\tSSRIs\t50~200\t改善认知功能；疗 效和耐受性相对 更为平衡\t同西酞普兰\t同西酞普兰\n文拉法辛\tSNRIs\t75~225\t高剂量时改善焦虑 症状\t恶心、失眠、口干、嗜睡、头晕、出汗、 紧张、头痛、性功能障碍、便秘\n　大剂量时血压升高 撤药症状常见\t1. 同西酞普兰；\n2. 监测血压；尽量使用最小有效剂 量；必要时加用降压药\n度洛西汀\tSNRIs\t60~ 120\t同文拉法辛；对伴 有躯体疼痛的抑 郁症有效\t恶心、失眠、头痛、头晕、口干、困倦、 便秘 、厌食 。心率和血压轻度增  加，包括高血压危象\t同文拉法辛\n米氮平\tNsSSA\t15~45\t胃肠道反应小；对 食欲和睡眠有改 善作用 ；对性功 能影响小\t食欲增加、体重增加、困倦、水肿、头 晕 、头痛 、白细胞减少 。恶心 、性 功能障碍相对少见\t1. 防摔伤；\n2. 服药期间监测血糖，控制饮食，加 强体育锻炼\n阿戈美拉汀\tMT受体激 动剂\t25~50\t耐受性好；对睡眠 有改善作用\t恶心 、头晕 、头痛 、失眠 、困倦 、偏头 痛、肝功能异常\t1. 肝功能异常慎用；\n2. 定期检测肝功能\n曲唑酮\t5?HT 调 节剂\t50~400\t对焦虑症状有效； 改善睡眠结构 ； 对性功能影响小\t镇静、头晕、头痛、恶心、呕吐、震颤、 体位性低血压、心动过速、阴茎异  常勃起\t1. 慎用镇静剂、酒精、地高辛、苯妥英；\n2. 禁止与 MAOIs 合用\n安非他酮\tNDRI\t150~450\t无体重增加的问 题 ；可用于性功 能障碍\t失眠、焦虑、激越、震颤、恶心、口干、 多汗、耳鸣和皮疹\t1. 高剂量时有增加惊厥的风险；\n2. 禁止与 MAOIs 合用\n　　注：SSRIs 选择性 5?羟色胺再摄取抑制剂；SNRIs 5?羟色胺和去甲肾上腺素再摄取抑制剂；NsSSA 去甲肾上腺素能和特异性 5?羟色胺能抗 抑郁剂；MT 褪黑素；5?HT 5?羟色胺；NDRI 去甲肾上腺素和多巴胺再摄取抑制剂；MAOIs 单胺氧化酶抑制剂；TCAs 三环类抗抑郁药\n\n湖南药事服务网\nhttp://www.hnysfww.com/\n\n　　中华全科医师杂志 2021 年 12 月第 20 卷第 12 期    Chin J Gen Pract, December 2021, Vol. 20, No. 12 表3  传统抗抑郁药和其他治�\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_338b0ba874bc69c33ed1d6d4c5bd229b06f9743a1a51f6a6c4263e6f98dc4449_v2"}